AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Go back to AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma| AbbVie (NYSE: ABBV) | Delayed: 261.48 +4.36 (1.70%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $257.12 | 52 Week High | $68.12 | |||
| Open | $261.67 | 52 Week Low | $50.71 | |||
| Day High | $264.65 | P/E | 56.72 | |||
| Day Low | $260.10 | EPS | $4.61 | |||
| Volume | 1,922,446 | |||||
